Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

MediGene, bluebird bio: $1 Billion+ Deal

MediGene and bluebird bio struck a collaborative deal to develop T cell receptor (TCR) immunotherapies against four targets that could be worth more than $1 billion.

Read More »

Hanmi Pharma Inks $910M Deal with Genentech

Genentech, a member of the Roche Group, licensed HM95573 from Seoul, South Korea-based Hanmi Pharmaceutical Co. for a deal that could hit $910 million.

Read More »

TechCrunch: Inspiring a different approach for pharma

Every once in a while it’s refreshing for a healthcare digital strategist or innovation officer to take a close look at how marketing technology is being used outside of pharma.

Read More »

Novo Nordisk to ax 1,000 jobs in cost-cutting drive

The world’s largest insulin maker, Novo Nordisk, is cutting 1,000 jobs as a part of a plan to reduce costs as it faces a challenging environment in 2017, especially in the large U.S. market.

Read More »

Actelion to investigate all-oral MS combination therapy

Swiss biotech group Actelion Ltd. will investigate an all-oral combination therapy for patients with relapsing multiple sclerosis (RMS), calling it the first study of this approach for treating the neurological disorder.

Read More »

FDA approves Medtronic’s ‘artificial pancreas’ for diabetes

Medtronic Plc won U.S. approval for an “artificial pancreas” that is the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes, freeing them from continually monitoring insulin levels throughout each day.

Read More »

In-office tests may detect hip tendon problems before MRI

Two simple tests that can be done in a doctor’s office may be able to rule in or out a painful hip condition that is usually hard to diagnose without magnetic resonance imaging (MRI), according to a small study.

Read More »

Senators ask Justice Dept to consider probe of EpiPen Medicaid classification

U.S. Senators Richard Blumenthal, Charles Grassley and Amy Klobuchar asked the Justice Department to investigate whether Mylan NV may have misclassified its EpiPen in order to pay lower rebates to the states.

Read More »

Boehringer boosts immune-oncology pipeline

Boehringer Ingelheim and ViraTherapeutics will jointly develop a next-generation oncolytic virus therapy platform and investigate ViraTherapeutics’ lead candidate.

Read More »

Biogen to Test Anavex’s Lead Drug Candidate

Biogen will test Anavex Life Sciences’ lead drug candidate, ANAVEX 2-73, in an oligodendrocyte precursor cell (OPC) differentiation assay.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!


Ad Right Bottom